These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
187 related items for PubMed ID: 16230180
1. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury. Davies B, Chen JJ, McMurry T, Landsittel D, Lewis N, Brenes G, Getzenberg RH. Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180 [Abstract] [Full Text] [Related]
3. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer. Raitanen MP, Leppilahti M, Tuhkanen K, Forssel T, Nylund P, Tammela T, FinnBladder Group. Ann Chir Gynaecol; 2001 Oct; 90(4):261-5. PubMed ID: 11820414 [Abstract] [Full Text] [Related]
4. [Comparative study of BTA stat test, NMP-22, and cytology in the diagnosis of bladder cancer]. Gutiérrez Baños JL, Rebollo Rodrigo MH, Antolín Juarez F, Martín García B, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, de Diego Rodríguez E, Radó Velázquez MA. Arch Esp Urol; 2000 Oct; 53(1):21-7. PubMed ID: 10730421 [Abstract] [Full Text] [Related]
5. [The BTA stat test in the follow-up for bladder cancer]. Gutiérrez Baños JL, Martín García B, de Diego Rodríguez E, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA, del Valle Schaan JI, Roca Edreira A, Rado Velázquez MA. Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117 [Abstract] [Full Text] [Related]
10. Noninvasive detection of bladder cancer with the BTA stat test. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. J Urol; 1999 Feb; 161(2):443-6. PubMed ID: 9915422 [Abstract] [Full Text] [Related]
11. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427 [Abstract] [Full Text] [Related]
12. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer. Davies B, Chen J, Modugno F, Weissfeld J, Landsittel D, Dhir R, Nelson J, Getzenberg RH. J Urol; 2005 Nov; 174(5):1767-70. PubMed ID: 16217280 [Abstract] [Full Text] [Related]
13. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer. Eissa S, Shabayek MI, Ismail MF, El-Allawy RM, Hamdy MA. IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180 [Abstract] [Full Text] [Related]
14. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage]. Rodríguez Martínez JJ, Escaf Barmadah S, Allende MT, Raigoso P, Martín Benito JL, Pérez García FJ, Fernández Gómez JM. Arch Esp Urol; 2000 May; 53(1):1-6. PubMed ID: 10730418 [Abstract] [Full Text] [Related]
15. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Kumar A, Kumar R, Gupta NP. Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358 [Abstract] [Full Text] [Related]